Shots:
- Following the EU approval of Remsima IV in Nov’25, Celltrion launched Remsima IV, a biosimilar version of Remicade (Infliximab), across Europe
- Celltrion has filed and secured patents for the Remsima liquid formulation across most EU countries, including key markets such as the UK, Germany, and France
- The Remsima liquid formulation adds to existing IV (100 mg lyophilized) and SC options, aligning with clinical demand in Europe for a multi-dose format that may simplify storage and preparation. Celltrion has introduced a 350 mg liquid version and is continuing its sales and marketing efforts. Celltrion also secured Nordic tender contracts in Denmark and Norway, with supply in Norway planned through Jan’28
Ref: Celltrion | Image: Celltrion | Press Release
Related News: Celltrion Plans to File for Approval of Herzuma SC (Biosimilar, Herceptin) in Europe and Korea
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
